MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
34.64
-0.75
-2.12%
Pre Market: 34.88 +0.24 +0.69% 08:22 11/11 EST
OPEN
34.45
PREV CLOSE
35.39
HIGH
35.97
LOW
33.78
VOLUME
261
TURNOVER
0
52 WEEK HIGH
49.70
52 WEEK LOW
10.46
MARKET CAP
4.65B
P/E (TTM)
-11.4725
1D
5D
1M
3M
1Y
5Y
1D
Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
TipRanks · 1h ago
Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated
Seeking Alpha · 19h ago
Definium Therapeutics reports Q3 EPS (46c), consensus (56c)
TipRanks · 20h ago
Definium Therapeutics Price Target Raised to $70.00/Share From $66.00 by RBC Capital
Dow Jones · 21h ago
Definium Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 21h ago
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $70
Benzinga · 22h ago
DEA looks to increase legal psychedelics production for medical research
Seeking Alpha · 22h ago
Definium Therapeutics: Clinical Progress, Pipeline Potential, and Strong Liquidity Support a Buy Rating
TipRanks · 1d ago
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.